AI in Oncology Market to Hit USD 11.52 Billion by 2030 Amid Rapid Advances in Cancer Diagnostics

According to DataM Intelligence, the global AI in oncology market was valued at USD 2.45 billion in 2024 and is projected to reach USD 11.52 billion by 2030, growing at a CAGR of 29.4% during the forecast period. The increasing prevalence of cancer, coupled with the rapid integration of artificial intelligence in cancer diagnosis, treatment planning, and drug discovery, is driving robust market expansion. AI tools in oncology accelerate diagnostic precision, optimize therapeutic decision-making, and significantly reduce the duration and cost of clinical processes.

The early detection of cancer remains a key area where AI has disrupted traditional workflows, helping clinicians predict disease progression and tailor treatment strategies. North America leads the market due to strong healthcare infrastructure, the presence of top AI solution providers, and rising adoption of precision medicine. The market outlook is further strengthened by technological advancements, government support for AI integration in healthcare, and increasing R&D investments by pharmaceutical and biotech companies.

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/ai-in-oncology-market?utm_source=OpenPR&utm_campaign=Onkar

Key Highlights from the Report

➤ Global AI in Oncology Market projected to reach USD 11.52 billion by 2030 with 29.4% CAGR
➤ North America led the market in 2023, supported by high AI adoption in cancer care
➤ Asia Pacific expected to grow at the fastest CAGR of 30.7% over the forecast period
➤ Diagnosis and early detection segment captured the largest market share in 2023
➤ Solid tumor segment dominated with extensive application in breast cancer detection
➤ GE Healthcare, Oracle, and ConcertAI among key innovators driving AI-based oncology solutions

Market Segmentation

Segmentation in the AI in oncology market is based on application, cancer type, and end-user. Diagnosis and early detection represented the largest segment in 2023 due to the increasing deployment of AI-powered image interpretation and predictive analytics that allow early identification and precision diagnosis of cancer. AI algorithms integrated with medical imaging and genomics notably enhance prediction accuracy, supporting timely and effective intervention.

By cancer type, solid tumors held the dominant market share in 2023, with applications primarily focused on breast, lung, and colorectal cancers. Breast cancer accounted for a significant portion of this segment, as AI-based models like deep learning and computer-aided detection systems improve tumor identification and diagnostic speed. Increasing emphasis on early-stage detection and better therapeutic precision is expected to keep this segment at the forefront through 2030.

Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/ai-in-oncology-market?utm_source=OpenPR&utm_campaign=Onkar

Regional Insights

North America remained the largest regional market in 2023, benefiting from the strong presence of AI-driven oncology solution providers such as GE Healthcare, ConcertAI, NVIDIA, and Oracle. The region's leading position is reinforced by well-established data infrastructure, ongoing clinical collaborations, and favorable regulations promoting AI-based medical innovation.

Asia Pacific is poised for the highest growth at a projected CAGR of 30.7%, driven by expanding digital healthcare ecosystems, government-backed R&D initiatives, and rising awareness about early cancer detection. Countries like Japan, China, and India are advancing national healthtech programs that accelerate AI integration in oncology diagnostics.

Market Dynamics

Market Drivers
The mounting global cancer burden is a primary driver propelling the adoption of AI-based oncology solutions. With more than 20 million new cancer cases recorded in 2022, the demand for technologies that reduce diagnostic errors and enable precision treatment is surging. AI's predictive power and automation support enhanced patient outcomes and cost efficiency in cancer management.

Market Restraints
High regulatory compliance costs and significant initial investments limit market accessibility, especially for small and medium AI providers. Data acquisition, licensing, and validation of clinical algorithms demand extensive expenditure, while data privacy regulations such as GDPR and HIPAA pose additional administrative burdens.

Market Opportunities
The growing focus on personalized treatment plans-driven by AI's ability to interpret genomic profiles, tumor mutations, and patient histories-presents major growth opportunities. AI-enabled therapy models, predictive diagnostics, and smart imaging assist clinicians in tailoring cancer treatments, reducing side effects, and improving patient survival rates.

Purchase This Exclusive Report at Just USD 5846 Only: https://www.datamintelligence.com/buy-now-page?report=ai-in-oncology-market?utm_source=OpenPR&utm_campaign=Onkar

Reasons to Buy the Report
✔ Comprehensive data on emerging AI solutions transforming global oncology
✔ In-depth segmentation covering cancer types, diagnostic applications, and regional markets
✔ Insights into major drivers, trends, restraints, and opportunities shaping future growth
✔ Detailed profiles and competitive strategies of top industry players
✔ Verified forecasts and industry analysis provided by DataM Intelligence experts

Frequently Asked Questions (FAQs)
◆ How big is the global AI in oncology market in 2024 and 2030?
◆ What is the projected CAGR of the AI in oncology market during 2024-2030?
◆ Who are the key players driving innovation in the AI in oncology industry?
◆ What are the main factors driving demand for early cancer detection using AI?
◆ Which region is anticipated to dominate the AI in oncology market during the forecast period?

Company Insights
GE Healthcare

Oracle Corporation

ConcertAI

NVIDIA Corporation

F. Hoffmann-La Roche Ltd.

Predictive Oncology

PathAI

CureMatrix

Azra AI

Triomics

Recent Developments:

May 2024: GE Healthcare introduced Revolution RT CT Solution and Intelligent Radiation Therapy platform to enhance precision and workflow efficiency.

June 2024: ConcertAI and NVIDIA partnered to boost translational and clinical oncology development through advanced AI-driven analytics.

Conclusion

The global AI in oncology market is entering a high-growth phase fueled by breakthroughs in data analytics, genomics, and imaging technologies. With demand skyrocketing for early cancer detection, precision medicine, and automated clinical workflows, AI is becoming integral to comprehensive cancer care. As established players and emerging innovators continue investing in advanced AI platforms, the industry is set to evolve into a cornerstone of modern oncology, offering faster diagnoses, tailored therapies, and improved patient outcomes by 2030.

Contact Us

Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com

About Us

DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.

This release was published on openPR.